144 related articles for article (PubMed ID: 31430337)
1. Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma.
Lämmer F; Delbridge C; Würstle S; Neff F; Meyer B; Schlegel J; Kessel KA; Schmid TE; Schilling D; Combs SE
PLoS One; 2019; 14(8):e0221502. PubMed ID: 31430337
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas.
Thorsteinsdottir J; Stangl S; Fu P; Guo K; Albrecht V; Eigenbrod S; Erl J; Gehrmann M; Tonn JC; Multhoff G; Schichor C
J Neurooncol; 2017 Dec; 135(3):443-452. PubMed ID: 28849427
[TBL] [Abstract][Full Text] [Related]
3. Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.
Muth C; Rubner Y; Semrau S; Rühle PF; Frey B; Strnad A; Buslei R; Fietkau R; Gaipl US
Strahlenther Onkol; 2016 Mar; 192(3):146-55. PubMed ID: 26646311
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
5. Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors.
Roy LO; Poirier MB; Fortin D
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642484
[TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A
Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031
[TBL] [Abstract][Full Text] [Related]
7. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
[TBL] [Abstract][Full Text] [Related]
8. Investigation of serum levels and tissue expression of two genes IGFBP-2 and IGFBP-3 act as potential biomarker for predicting the progression and survival in patients with glioblastoma multiforme.
Abdolhoseinpour H; Mehrabi F; Shahraki K; Khoshnood RJ; Masoumi B; Yahaghi E; Goudarzi PK
J Neurol Sci; 2016 Jul; 366():202-206. PubMed ID: 27288807
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.
Vassilakopoulou M; Won M; Curran WJ; Souhami L; Prados MD; Langer CJ; Rimm DL; Hanna JA; Neumeister VM; Melian E; Diaz AZ; Atkins JN; Komarnicky LT; Schultz CJ; Howard SP; Zhang P; Dicker AP; Knisely JPS
Oncology; 2021; 99(9):580-588. PubMed ID: 33957633
[TBL] [Abstract][Full Text] [Related]
11. The hedgehog antagonist HHIP as a favorable prognosticator in glioblastoma.
Chang L; Zhang P; Zhao D; Liu H; Wang Q; Li C; Du W; Liu X; Zhang H; Zhang Z; Jiang C
Tumour Biol; 2016 Mar; 37(3):3979-86. PubMed ID: 26482617
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and Flow Cytometric Analysis of Intracellular and Membrane-Bound Hsp70, as a Putative Biomarker of Glioblastoma Multiforme, Using the cmHsp70.1 Monoclonal Antibody.
Stangl S; Foulds GA; Fellinger H; Pilkington GJ; Pockley AG; Multhoff G
Methods Mol Biol; 2018; 1709():307-320. PubMed ID: 29177668
[TBL] [Abstract][Full Text] [Related]
13. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of fascin expression in a newly diagnosed primary glioblastoma.
Park KS; Lee HW; Park SH; Park TI; Hwang JH
J Neurooncol; 2016 Sep; 129(3):495-503. PubMed ID: 27406586
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Li S; Zhang W; Chen B; Jiang T; Wang Z
Neurol Res; 2010 Sep; 32(7):690-4. PubMed ID: 19703338
[TBL] [Abstract][Full Text] [Related]
16. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
[TBL] [Abstract][Full Text] [Related]
17. Chemokine receptor CXCR7 is an independent prognostic biomarker in glioblastoma.
Deng L; Zheng W; Dong X; Liu J; Zhu C; Lu D; Zhang J; Song L; Wang Y; Deng D
Cancer Biomark; 2017 Jul; 20(1):1-6. PubMed ID: 28759950
[TBL] [Abstract][Full Text] [Related]
18. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma.
An G; Ahn S; Park JS; Jeun SS; Hong YK
J Cancer Res Clin Oncol; 2021 Mar; 147(3):901-909. PubMed ID: 32929611
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
20. STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma.
Lin GS; Chen YP; Lin ZX; Wang XF; Zheng ZQ; Chen L
Int J Clin Exp Pathol; 2014; 7(6):3141-9. PubMed ID: 25031733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
